Truist Securities reiterates Buy rating on Chemours stock, maintains $21 price target

Truist Securities reiterated a Buy rating on Chemours (NYSE:CC) with a $21.00 price target, citing secular growth in its Thermal & Specialized Solutions business and earnings upside from self-help actions, despite the stock's recent 9.88% decline. While uncertainty surrounding PFAS liabilities remains a key overhang, management expects resolution clarity by 2026-27, a view somewhat supported by Mizuho's recent price target increase to $19.00 on an improved PFAS outlook. The company is also undergoing leadership transitions, with a new Board Chair appointed for 2025 and a search underway for a new CEO following Dawn Farrell's resignation.

Analysis

Despite a significant -9.88% stock price decline over the past week to $15.63, Chemours (NYSE:CC) has received a reiterated Buy rating from Truist Securities with a maintained price target of $21.00. The firm's positive outlook is based on two primary factors: anticipated secular growth in the Thermal & Specialized Solutions (TSS) division, fueled by regulatory adoption and new products, and potential for substantial earnings improvement in cyclical segments like titanium dioxide (TiO2) through internal self-help measures. This bullish sentiment is partially echoed by Mizuho, which recently raised its price target to $19.00 from $16.00 and maintained an Outperform rating, specifically citing an improved outlook on the company's per- and polyfluoroalkyl substances (PFAS) liabilities. However, this PFAS uncertainty remains the primary overhang on the company's valuation. Chemours' management has guided that it expects greater clarity on the resolution of these liabilities to emerge between 2026 and 2027. The company is also navigating a leadership transition, with Mary Cranston appointed as the new Board Chair effective September 2025, following Dawn Farrell's resignation; a search for a new CEO is currently underway, adding an element of execution uncertainty.

Key Decisions for Investors

• Investors should evaluate Chemours as a high-risk, high-reward opportunity, weighing the strong underlying fundamentals in its TSS and TiO2 businesses against the significant valuation discount caused by the unresolved PFAS liability overhang.
• Closely monitor all news flow and legal proceedings related to PFAS, as any progress toward a resolution, particularly within the 2026-27 timeframe guided by management, represents the primary catalyst for a potential re-rating of the stock.
• The ongoing search for a new CEO introduces execution risk; therefore, it is crucial to assess the incoming leader's strategic plan for managing the company's cyclical segments and navigating the complex liability situation.